You are here

AcelRx’s Pain Drug Meets Goal in Pivotal Trial

Sublingual tablet treats moderate-to-severe acute pain following ambulatory abdominal surgery

AcelRx Pharmaceuticals’s  ARX-04 (sufentanil sublingual tablet, 30 mcg) met primary and secondary endpoints in a multicenter, double-blind, placebo-controlled phase III trial (SAP301) designed to study the short-term treatment of patients with moderate-to-severe acute pain following ambulatory abdominal surgery.

Results demonstrated that patients receiving ARX‑04, administered via a disposable, pre-filled, single-dose applicator, experienced significantly greater pain reduction compared with placebo, as measured by the time-weighted summed pain intensity difference over the first 12 hours of treatment (SPID-12) (P < 0.001). Adverse events reported in the study were typical of opioid therapy and were similar for patients treated with ARX-04 and placebo; the most common were nausea, headache, and vomiting.

SAP301 enrolled adult patients undergoing outpatient abdominal surgery procedures at four U.S. clinical sites. Following surgery, 163 patients were randomized to receive either ARX-04 or placebo in a 2:1 ratio. ARX-04 or placebo was administered by site staff as requested by the patient, but no more than once per hour. The intent-to-treat population had an average age of 40.9 years and an average body mass index of 27.5; 68% were female). Eighty-nine percent of patients entering the study completed the 24-hour study period.

The primary endpoint of the study was the difference in the SPID-12 score of patients receiving ARX-04 compared to those receiving placebo. SPID‑12 scores were +25.8 for ARX-04-treated patients and +13.1 for placebo-treated patients (P < 0.001). The difference in pain intensity from baseline was superior for ARX-04 over placebo at the earliest time point measured (15 minutes; P = 0.002). Secondary efficacy endpoints, which will be presented at the upcoming American Society of Anesthesiologists Annual Meeting, were also superior for ARX-04 compared to placebo.

Two serious adverse events were reported during the study; both were in the placebo group and resulted in early termination of the affected patients. No patient in the ARX-04 group dropped out of the study prior to 24 hours due to an adverse event. A lower percentage of patients treated with ARX-04 dropped out of the study prior to 24 hours due to lack of efficacy compared to the placebo group (3.7% and 18.5%, respectively; P = 0.002).

Although this trial was conducted in the ambulatory surgery setting, AcelRx plans to initiate a study later this year for emergency room patients.

Source: AcelRx; September 9, 2015.

Recent Headlines

NY Hospitals Required to Implement Protocols in Suspected Cases
Presence of BOK Protein Key for Positive Treatment Response
Patient Access to Inhaler Use Data Could Improve Asthma Management
Overall Survival 4.3 Months’ vs. 1.5 Months for Traditional Regimens
Primary Immunodeficiencies Affect 250,000 People in U.S.
More Than 25% of Patients Responded to Xpovio/Dexamethasone Combo
Attacks Cancerous Cells, Leaves Healthy Tissues Alone
Moderates Pre-diabetes Progression, Reduces Cholesterol Levels